We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

This study has been terminated.
(Study terminated by University of Miami Institutional Review Board)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00449163
First Posted: March 19, 2007
Last Update Posted: May 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University of Miami
  Purpose

RATIONALE: Drugs used in chemotherapy, such as irinotecan, floxuridine, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of colorectal cancer by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with bevacizumab works in treating patients with stage IV colorectal cancer.


Condition Intervention Phase
Colorectal Cancer Biological: Bevacizumab Drug: Floxuridine Drug: Irinotecan Drug: Leucovorin Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Avastin, Irinotecan, High Dose 24 Hour Continuous Intravenous Infusion of Floxuridine and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer

Resource links provided by NLM:


Further study details as provided by University of Miami:

Primary Outcome Measures:
  • Overall Survival up to 2 Years [ Time Frame: 2 years ]
    Percentage of patients with overall survival times of up to 2 years


Secondary Outcome Measures:
  • Response Rate (Complete Response and Partial Response) [ Time Frame: 2 years ]
    Percentage of patients achieving complete response or partial response per RECIST criteria ver 1.0

  • Median Progression-free Survival in Months [ Time Frame: 2 years ]
    Median number of months subjects achieved progression-free survival

  • Rate of Toxicity in Study Participants [ Time Frame: 2 years ]
    Evaluation the safety and toxicities of protocol regimen as evidenced by the rate of serious adverse events in study participants.


Enrollment: 25
Actual Study Start Date: March 1, 2006
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Combination Chemotherapy and Bevacizumab

Treatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29:

  • Bevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22;
  • Irinotecan: 110 mg/m^2 via IV infusion on Days 1, 8, 22, 29;
  • Leucovorin: 500 mg/m^2 via IV infusion on Days 1, 8, 22 and 29;
  • Floxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29.
Biological: Bevacizumab
Other Name: Avastin
Drug: Floxuridine
Other Name: 5-fluorodeoxyuridine
Drug: Irinotecan
Other Names:
  • Irinotecan Hydrochloride
  • Camptosar
Drug: Leucovorin
Other Name: Leucovorin calcium

Detailed Description:

For the purpose of this study treatment cycle consist of six weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29 according to the schedule. There will be no treatment delivered on weeks 3 & 6 (Days 15 and 36).

Disease will be evaluated by CT scan at the completion of every two cycles. Patients with complete response (CR), or partial response (PR), will be evaluated for possible surgical resection. Patients who become operable will continue to be evaluated for survival and disease relapse. Patients with stable disease (SD), and those with less than pCR after surgery should continue chemotherapy until radiographic evidence of tumor progression is identified or unacceptable side effects.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must have stage IV, histologically confirmed diagnosis of Adenocarcinoma of the colon.
  2. Patients must have bi-dimensionally measurable disease since the purpose of this study is to determine efficacy of treatment.
  3. Patients must be previously untreated.
  4. Patients must be over the age of 18 years.
  5. Patients may not be pregnant. Patients of childbearing years must be using contraception.
  6. Patients must have ECOG performance status of 0-1 or KPS of at least 70.
  7. Patients must have life expectancy of ≥ two months.
  8. Patients must have a white blood cell count of ≥1000/mm³ ANC > 1.0, platelets > 100,000/mm³.
  9. Patients must have adequate renal function as documented by a serum creatinine of ≤ 1.5 mg/dl.
  10. Patients must have a bilirubin of ≤ 1.5 mg/dl and an SGOT of ≤ three times normal for patients with no liver disease, and ≤ five times normal for those with liver metastases.
  11. Patients must be informed of the investigational nature of the study and give written informed consent.
  12. Patients must have indwelling central venous catheter or good peripheral intravenous catheter, preferably a port-a-cath.
  13. Patients may have had prior surgery for their colorectal cancer. Patients must be at least 8 weeks beyond surgery and recovered from all effects of surgery.
  14. Patients enrolled in this study may have a history of prior malignancy (5 years ago) provided that the patient is currently disease-free.

Exclusion Criteria:

  1. Patients who have had prior chemotherapy or radiation therapy for their colorectal cancer, with exception of adjuvant chemo/radiation therapy.
  2. Patients receiving concomitant radiation, hormonal therapy, chemotherapy, or immunotherapy.
  3. Patients receiving any investigational drug within 30 days prior to start of this study.
  4. Patients with serious underlying medical illnesses (including Congestive Heart Failure New York Heart Association Functional Classification 2-4) or active infection.
  5. Patients with central nervous system metastasis must have completed radiation prior to entry into this protocol.
  6. Patients with psychiatric conditions or associated conditions which would make participating in this study dangerous to their health.
  7. Patients with uncontrolled hypertension.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00449163


Locations
United States, Florida
University of Miami
Miami, Florida, United States, 33136
Sponsors and Collaborators
University of Miami
Investigators
Principal Investigator: Bach Ardalan, MD University of Miami
  More Information

Additional Information:
Publications:
Phase II study of bevacizumab (B), camptosar (I), high-dose 24-hour continuous intravenous infusion of floxuridine (F) and leucovorin (L) in patients with previously untreated metastatic colon cancer. (B-IFL) B. Ardalan, M. Feagans, D. Mezentsev, C. Jones, P. R. Subbarayan, G. Walker, M. Sapp, K. Stephenson, J. Ness, D. Franceschi, and A. Livingstone Journal of Clinical Oncology 2009 27:15S, e15114-e15114

Responsible Party: University of Miami
ClinicalTrials.gov Identifier: NCT00449163     History of Changes
Other Study ID Numbers: 20060042
SCCC-2005145 ( Other Identifier: University of Miami Sylvester Comprehensive Cancer Center )
WIRB-20060252 ( Other Identifier: Western Institutional Review Board )
First Submitted: March 15, 2007
First Posted: March 19, 2007
Results First Submitted: January 23, 2013
Results First Posted: February 28, 2013
Last Update Posted: May 11, 2017
Last Verified: April 2017

Keywords provided by University of Miami:
stage IV colon cancer
stage IV rectal cancer
adenocarcinoma of the colon
adenocarcinoma of the rectum

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Bevacizumab
Irinotecan
Camptothecin
Floxuridine
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antimetabolites